Sampada Chande1, Francina Dijk2, Jonathan Fetene1, Steven Yannicelli3, Thomas O Carpenter4, Ardy van Helvoort5, Clemens Bergwitz6. 1. Yale University School of Medicine, Section of Endocrinology and Metabolism, New Haven, Connecticut, USA. 2. Danone Nutricia Research, Utrecht, The Netherlands. 3. Nutricia North America, Rockville, Maryland, USA. 4. Yale University School of Medicine, Department of Pediatrics, New Haven, Connecticut, USA. 5. Danone Nutricia Research, Utrecht, The Netherlands; School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. 6. Yale University School of Medicine, Section of Endocrinology and Metabolism, New Haven, Connecticut, USA. Electronic address: clemens.bergwitz@yale.edu.
Abstract
OBJECTIVE: The aim of this study was to quantify the bioaccessibility of phosphorus from amino acid-based formulas (AAFs) under different digestive conditions. METHODS: We developed in-vitro batch digestion models with stomach digestion at different pH mimicking the normal digestive condition and conditions representing use of acid-suppressive medication. To validate bioaccessibility findings, we devised a low phosphorus murine model to test phosphorus bioavailability under compromised digestive conditions using proton pump inhibitors (PPIs) to neutralize stomach pH. RESULTS: In vitro phosphorus bioaccessibility of AAFs Neocate® Infant and Neocate Junior ranged between 57% and 65% under normal digestive conditions for infants (stomach pH 3.5) and between 38% and 46% under conditions that simulated bypass of stomach acidification, which is comparable to control diet and two EleCare® AAFs. In vivo bioavailability analysis showed that both Neocate formulas were able to normalize plasma phosphorus levels when administered to low phosphorus mice along with PPIs (control diet + PPI 8 ± 0.4; Neocate Infant 10.1 ± 0.9; Neocate Junior 9.2 ± 0.6; EleCare Infant 8.6 ± 0.4; EleCare Junior 8.7 ± 0.5; n = 8-10; P < 0.0001 versus baseline 3.4 ± 0.2 mg/dL). In comparison, plasma phosphorus levels remained lower on the low phosphorus diet (5.7 ± 0.2 mg/dL). Furthermore, urinary phosphorus/creatinine and intact fibroblast growth factor 23 were significantly lowered by low phosphorus diet. In contrast, intact parathyroid hormone and 1,25-dihydroxy vitamin D decreased and increased, respectively, and these parameters likewise normalized in mice administered AAFs. CONCLUSION: The present findings indicated that phosphorus bioaccessibility in the in-vitro batch digestion model translates well into phosphorus bioavailability in mice even under compromised digestive conditions that bypass gastric acidification.
OBJECTIVE: The aim of this study was to quantify the bioaccessibility of phosphorus from amino acid-based formulas (AAFs) under different digestive conditions. METHODS: We developed in-vitro batch digestion models with stomach digestion at different pH mimicking the normal digestive condition and conditions representing use of acid-suppressive medication. To validate bioaccessibility findings, we devised a low phosphorus murine model to test phosphorus bioavailability under compromised digestive conditions using proton pump inhibitors (PPIs) to neutralize stomach pH. RESULTS: In vitro phosphorus bioaccessibility of AAFs Neocate® Infant and Neocate Junior ranged between 57% and 65% under normal digestive conditions for infants (stomach pH 3.5) and between 38% and 46% under conditions that simulated bypass of stomach acidification, which is comparable to control diet and two EleCare® AAFs. In vivo bioavailability analysis showed that both Neocate formulas were able to normalize plasma phosphorus levels when administered to low phosphorus mice along with PPIs (control diet + PPI 8 ± 0.4; Neocate Infant 10.1 ± 0.9; Neocate Junior 9.2 ± 0.6; EleCare Infant 8.6 ± 0.4; EleCare Junior 8.7 ± 0.5; n = 8-10; P < 0.0001 versus baseline 3.4 ± 0.2 mg/dL). In comparison, plasma phosphorus levels remained lower on the low phosphorus diet (5.7 ± 0.2 mg/dL). Furthermore, urinary phosphorus/creatinine and intact fibroblast growth factor 23 were significantly lowered by low phosphorus diet. In contrast, intact parathyroid hormone and 1,25-dihydroxy vitamin D decreased and increased, respectively, and these parameters likewise normalized in mice administered AAFs. CONCLUSION: The present findings indicated that phosphorus bioaccessibility in the in-vitro batch digestion model translates well into phosphorus bioavailability in mice even under compromised digestive conditions that bypass gastric acidification.
Authors: Clemens Bergwitz; Simone R B M Eussen; Pilou L H R Janssens; Monique Visser; Thomas O Carpenter; Ardy van Helvoort Journal: Nutr Res Date: 2020-11-18 Impact factor: 3.315
Authors: S Uday; S Sakka; J H Davies; T Randell; V Arya; C Brain; M Tighe; J Allgrove; P Arundel; R Pryce; W Högler; N J Shaw Journal: Clin Nutr Date: 2018-09-28 Impact factor: 7.324
Authors: Yves Sabbagh; Stephen P O'Brien; Wenping Song; Joseph H Boulanger; Adam Stockmann; Cynthia Arbeeny; Susan C Schiavi Journal: J Am Soc Nephrol Date: 2009-09-03 Impact factor: 10.121
Authors: Yuwen Li; Daniel Caballero; Julian Ponsetto; Alyssa Chen; Chuanlong Zhu; Jun Guo; Marie Demay; Harald Jüppner; Clemens Bergwitz Journal: PLoS One Date: 2017-04-27 Impact factor: 3.240